Next Generation News and Research

RSS

Joubert Syndrome - an inherited neurological disease found among Ashkenazi Jews

Two scientists from Cold Spring Harbor Laboratory (CSHL) are part of an international team that has discovered a genetic mutation that causes Joubert Syndrome. JBTS, as it is commonly called, is a devastating inherited neurological disease that is very rare in the general population but found relatively more often among Ashkenazi Jews.

18 Jan 2010

Monsanto and Stokes Bio announce licensing agreement and R&D collaboration

Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.

13 Jan 2010

Kapa Biosystems signs non-exclusive North American distribution agreement with VWR International

Kapa Biosystems and VWR International, LLC announced today that they have entered into a non-exclusive North American distribution agreement for Kapa Biosystems' line of next-generation PCR reagents.

13 Jan 2010

KKESH in Saudi Arabia and U.S. Johns Hopkins Medicine announce collaboration

The Wilmer Eye Institute of Johns Hopkins Medicine in Baltimore (USA) announced today that it will collaborate in research, education and patient care with the King Khaled Eye Specialist Hospital in Riyadh (Saudi Arabia).

12 Jan 2010

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

QIAGEN N.V. today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

From QIAGEN Manchester Limited 12 Jan 2010

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Trubion Pharmaceuticals, Inc. today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus (SLE).

12 Jan 2010

Positive results from KemPharm's KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm’s proprietary Ligand Activated Therapy (LAT) prodrug approach.

12 Jan 2010

Illumina launches HumanOmniExpress BeadChip for GWAS

Illumina, Inc. today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

From Illumina, Inc. 11 Jan 2010

Interest in studying psychology on the rise

"I hope I will be able to touch the lives of people when they most need help and to offer them advice and guidance."

9 Jan 2010

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Los Alamos National Laboratory (www.lanl.gov) has identified the Top 10 Laboratory science stories of 2009 based on global viewership of online media content and major programmatic milestones.

9 Jan 2010

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Acetylon Pharmaceuticals, Inc. announced today that it has closed on a $2 million investment from a new undisclosed private investor to bring its total financing to $9.25 million. This new investment will convert to stock in the next substantial round of preferred equity financing.

9 Jan 2010

Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System receives Japanese marketing approval

Boston Scientific Corporation announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its PROMUS® Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The Company plans to launch the product as soon as reimbursement approval is granted, which is expected in the coming weeks.

9 Jan 2010

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Abbott announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V® Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

8 Jan 2010

Gore's next generation Conformable GORE TAG Thoracic Endoprosthesis enters clinical trial

W. L. Gore & Associates (Gore) announced the first human implants of the next generation Conformable GORE TAG® Thoracic Endoprosthesis in the United States for the treatment of traumatic transection of the thoracic aorta.

8 Jan 2010

Vignet releases Connected Health Services platform infrastructure for mHealth devices and services

Vignet Inc., today announced its Connected Health Services platform infrastructure for mobile health (mHealth) devices and services. The new “person-centered” platform allows users to capture, aggregate, analyze and share data with their mobile devices, leveraging any wired or wireless interface, such as Bluetooth, ZigBee, Bluetooth LE and USB.

7 Jan 2010

SMART Modular Technologies releases XceedIOPS SATA

SMART Modular Technologies (WWH), Inc. ("SMART" or the "Company"), a leading independent manufacturer of memory modules and solid-state storage products, including solid-state drives (SSDs), today announced the XceedIOPS SATA, its next-generation enterprise-class SSD.

6 Jan 2010

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Agilent Technologies, Inc. (NYSE:A) and Covaris Inc. today announced a co-marketing agreement in which Covaris S2 DNA shearing technology will be marketed with the Agilent SureSelect Target Enrichment System to streamline next-generation sequencing experiments.

6 Jan 2010

Innexus Biotechnology designs new psoriasis product

InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.

6 Jan 2010

UC San Diego bioengineering professor receives 2009 Presidential Science Prize

For Shu Chien - a pioneer in the growing field of bioengineering - understanding and learning the marvels of how the human body works has been the foundation of his decades-long quest to advance science and technology worldwide. The UC San Diego bioengineering professor's significant scientific endeavors have paved the way for recognition of his renowned work at the university's Jacobs School of Engineering and abroad.

6 Jan 2010

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.

6 Jan 2010

Next Generation News and Research

Joubert Syndrome - an inherited neurological disease found among Ashkenazi Jews

Monsanto and Stokes Bio announce licensing agreement and R&D collaboration

Kapa Biosystems signs non-exclusive North American distribution agreement with VWR International

KKESH in Saudi Arabia and U.S. Johns Hopkins Medicine announce collaboration

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Positive results from KemPharm's KP106 Phase 1 clinical trial for ADHD

Illumina launches HumanOmniExpress BeadChip for GWAS

Interest in studying psychology on the rise

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System receives Japanese marketing approval

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Gore's next generation Conformable GORE TAG Thoracic Endoprosthesis enters clinical trial

Vignet releases Connected Health Services platform infrastructure for mHealth devices and services

SMART Modular Technologies releases XceedIOPS SATA

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Innexus Biotechnology designs new psoriasis product

UC San Diego bioengineering professor receives 2009 Presidential Science Prize

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News